Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma
- 27 Downloads
To determine the factors that may affect the accuracy of vitrectomy cell block technique in detecting atypical lymphoid cells in patients with vitreoretinal lymphoma (VRL).
We retrospectively reviewed 43 eyes in 39 patients who underwent vitrectomy for definitive histological diagnosis of VRL with vitrectomy cell block technique and/or smear preparation at Kyushu University Hospital from January 2001 to March 2016. The association of detection of atypical lymphoid cells using vitrectomy cell block technique with the following factors was assessed using logistic regression analysis: age at diagnosis, sex, presence or absence of concurrent cataract surgery with vitrectomy, clinical grading of vitreous haze, presence or absence of subretinal tumor infiltration, interval between initial symptoms and vitrectomy, and presence or absence of systemic corticosteroid therapy before vitrectomy.
Atypical lymphoid cells were more significantly detected using vitrectomy cell block technique compared to that using smear preparation (p = 0.018). After adjusting for age and sex, concurrent cataract surgery (odds ratio [OR], 10.41; 95% confidence interval [CI], 1.42–76.41) and subretinal tumor infiltration (OR, 5.06; 95% CI, 1.06–24.32) were significantly associated with failure of histological analysis with vitrectomy cell blocks. In multivariable logistic regression analysis, similar results were obtained, although subretinal tumor infiltration was only marginally associated with the detective capability of the technique.
Vitrectomy cell block technique significantly improved the definitive diagnosis of VRL. Concurrent cataract surgery with vitrectomy and subretinal tumor infiltration were risk factors for failure in vitrectomy cell blocks.
KeywordsSingle-center study Vitreoretinal lymphoma Vitrectomy cell block technique Concurrent cataract surgery Subretinal tumor infiltration
The atuhors thank Dr. Tatsuro Ishibashi for helpful suggestions.
This study was supported by a grant from JSPS KAKENHI Grant Number 15K10896 and 18K09471 [grants C (A.T.)] from the Ministry of Education, Science, Sports and Culture, and Japan and the Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical’s Founder (A.T.), Novartis Pharma Research Grants (AT), and Alcon Pharma Research Grants (AT).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the Kyushu University Institutional Review Board for Clinical Research. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed concent was obtained.
- 4.Chan CC, Sen HN (2013) Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 15:93–100Google Scholar
- 8.Hashida N, Nakai K, Saitoh N, Nishida K (2014) Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol 252:687–693. https://doi.org/10.1007/s00417-014-2584-8 CrossRefGoogle Scholar
- 10.Ma WL, Hou HA, Hsu YJ, Chen YK, Tang JL, Tsay W, Yeh PT, Yang CM, Lin CP, Tien HF (2016) Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. Ann Hematol 95:593–601. https://doi.org/10.1007/s00277-015-2582-x CrossRefGoogle Scholar
- 11.Akiyama H, Takase H, Kubo F, Miki T, Yamamoto M, Tomita M, Mochizuki M, Miura O, Arai A (2016) High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Sci 107:1458–1464. https://doi.org/10.1111/cas.13012 CrossRefGoogle Scholar
- 12.Kaburaki T, Taoka K, Matsuda J, Yamashita H, Matsuda I, Tsuji H, Tanaka R, Nakazaki K, Nakamura F, Kamiya K, Kurokawa M, Ohtomo K, Aihara M (2017) Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br J Haematol 179:246–255. https://doi.org/10.1111/bjh.14848 CrossRefGoogle Scholar
- 13.Kreher S, Strehlow F, Martus P, Roth P, Hertenstein B, Roth A, Birnbaum T, Griesinger F, Rauch M, Kanz L, Thiel E, Weller M, Korfel A (2015) Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. Ann Hematol 94:409–414. https://doi.org/10.1007/s00277-014-2212-z CrossRefGoogle Scholar
- 14.Lee S, Kim MJ, Kim JS, Oh SY, Kim SJ, Kwon YH, Chung IY, Kang JH, Yang DH, Kang HJ, Yoon DH, Kim WS, Kim HJ, Suh C (2015) Intraocular lymphoma in Korea: the consortium for improving survival of lymphoma (CISL) study. Blood Res 50:242–247. https://doi.org/10.5045/br.2015.50.4.242 CrossRefGoogle Scholar
- 29.Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS (2011) Primary vitreoretinal lymphoma: a report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 16:1589–1599. https://doi.org/10.1634/theoncologist.2011-0210 CrossRefGoogle Scholar
- 31.Takeda A, Yoshikawa H, Fukuhara T, Hikita S, Hijioka K, Otomo T, Arita R, Hisatomi T, Kimura K, Yoshida S, Kawano Y, Sonoda KH, Ishibashi T (2015) Distinct profiles of soluble cytokine receptors between B-cell vitreoretinal lymphoma and uveitis. Invest Ophthalmol Vis Sci 56:7516–7523. https://doi.org/10.1167/iovs.15-17465 CrossRefGoogle Scholar
- 35.Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T (2002) Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol 240:423–429. https://doi.org/10.1007/s00417-002-0454-2 CrossRefGoogle Scholar
- 37.Davis JL, Ruiz P Jr, Shah M, Mandelcorn ED (2012) Evaluation of the reactive T-cell infiltrate in uveitis and intraocular lymphoma with flow cytometry of vitreous fluid (an American ophthalmological society thesis). Trans Am Ophthalmol Soc 110:117–129Google Scholar
- 39.Bonzheim I, Giese S, Deuter C, Susskind D, Zierhut M, Waizel M, Szurman P, Federmann B, Schmidt J, Quintanilla-Martinez L, Coupland SE, Bartz-Schmidt KU, Fend F (2015) High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood 126:76–79. https://doi.org/10.1182/blood-2015-01-620518 CrossRefGoogle Scholar